Login / Register The Most Trusted Name in Medical Education

Urology

Improve your knowledge in the field of urology by taking one of Elsevier's complimentary continuing medical education courses.

2017 23 Modules 3 116x140

Evolving Paradigms for Managing Prostate Cancer: Implementing Multimodal Therapy in the Community Setting

Format: Webcast

Over the past 13 years, several new agents have been approved to treat patients with metastatic prostate cancer (PC). As a result, clinical guidelines have been updated frequently that support the expanding the role of combination therapy, particularly by introducing chemotherapy earlier to patients with castrate-sensitive progressive disease. Community urologists often treat PC patients many years before the development of progressive disease, and a growing number of urologists have successfully implemented advanced prostate cancer clinics (APCCs) within their practice setting in order to do so. This interactive activity will discuss the benefits of creating an APCC as well as all of the infrastructure requirements and practical considerations for administering chemotherapy in an office setting, as well as the financial ramifications of this investment in time and resources.

Take Course »

Credits: 1.0 AMA PRA Category 1 Credit™
138 17 287 JS 140x117

Immunotherapy: The Wave of the Future in Bladder Cancer?

Format: Supplement

This article reviews the role of immunotherapy in the treatment of locally advanced and metastatic urothelial cell carcinoma (UC). It describes the basic principles of cancer immunotherapy, as they relate to management of UC, and summarizes clinical data on current and investigational therapeutic approaches. Two immune checkpoint inhibitors are now approved for treatment of advanced UC in the United States, and the article discusses their unique response patterns and side effect profiles to help oncology clinicians appropriately incorporate these agents into patient care.

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
910750 116 x 140

ESMO 2017: A Therapeutic Update on the Management of Patients with Metastatic Renal Cell Carcinoma

Format: Medical Meeting Reporter

This webcast on metastatic renal cell carcinoma (mRCC) is based on a roundtable discussion among three key opinion leaders in the field. The experts will present updates on the management of mRCC and summarize and discuss the latest clinical trial data presented during the ESMO 2017 Congress, held in Madrid, Spain, on September 8–12, 2017. Advances in the use of targeted therapies such as VEGFR inhibitors, novel immunotherapies, and combination therapies including PD-1/PD-L1 and CTLA4 targeting agents will be examined. The experts will address the question of how novel treatment options could be included in individualized treatment plans when approved, to optimize treatment selection and outcomes for patients with mRCC.

Take Course »

 

Credits: 1.0 AMA PRA Category 1 Credit™